Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. Newsroom/
    3. Oncology/
    4. New Data from Phase 3 PAPILLON Study Show RYBREVANT®▼ (amivantamab) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lu
    Oncology

    New Data from Phase 3 PAPILLON Study Show RYBREVANT®▼ (amivantamab) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lu

    New Data from Phase 3 PAPILLON Study Show RYBREVANT®▼ (amivantamab) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer